SRP-9001

Sarepta Enters Uncharted Territory with Adcomm Approval
Sarepta Enters Uncharted Territory with Adcomm Approval
BioSpace
Sarepta Therapeutics
SRP-9001
DMD
Duchenne Muscular Dystrophy
FDA
gene therapy
Flag link:
Sarepta, days out from critical FDA meeting, lists questions expected at gene therapy AdComm
Sarepta, days out from critical FDA meeting, lists questions expected at gene therapy AdComm
Fierce Biotech
Sarepta Therapeutics
FDA
SRP-9001
DMD
Duchenne Muscular Dystrophy
Flag link:
Go or no go? Sarepta’s gene therapy faces scrutiny
Go or no go? Sarepta’s gene therapy faces scrutiny
EP Vantage
Sarepta Therapeutics
gene therapy
SRP-9001
Roche
DMD
Duchenne Muscular Dystrophy
Flag link:
FDA Reverses Course; Will Hold Adcomm for Sarepta’s DMD Gene Therapy
FDA Reverses Course; Will Hold Adcomm for Sarepta’s DMD Gene Therapy
BioSpace
FDA
Sarepta Therapeutics
DMD
gene therapy
Duchenne Muscular Dystrophy
SRP-9001
Flag link:
Duchenne muscular dystrophy: major trials and events to watch in 2023
Duchenne muscular dystrophy: major trials and events to watch in 2023
Clinical Trials Arena
DMD
Duchenne Muscular Dystrophy
clinical trials
gene therapy
FDA
Sarepta Therapeutics
SRP-9001
FibroGen
pamrevlumab
Capricor
CAP-1002
Santhera
ReveraGen
vamorolone
Flag link:
Sarepta's DMD gene therapy inches closer to market as FDA declines to hold advisory meeting
Sarepta's DMD gene therapy inches closer to market as FDA declines to hold advisory meeting
Fierce Biotech
FDA
Sarepta Therapeutics
SRP-9001
gene therapy
DMD
Duchenne Muscular Dystrophy
Flag link:
Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal
Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal
Endpoints
Sarepta Therapeutics
SRP-9001
gene therapy
Duchenne Muscular Dystrophy
CDMOs
Catalent
Flag link:
FDA grants speedy review to Sarepta’s Duchenne gene therapy
FDA grants speedy review to Sarepta’s Duchenne gene therapy
BioPharma Dive
Sarepta Therapeutics
SRP-9001
FDA
Duchenne Muscular Dystrophy
Flag link:
Sarepta preps $1.2B war chest as DMD gene therapy nears accelerated FDA nod
Sarepta preps $1.2B war chest as DMD gene therapy nears accelerated FDA nod
Fierce Biotech
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-9001
gene therapy
Flag link:
Sarepta asks FDA to approve first gene therapy for Duchenne muscular dystrophy
Sarepta asks FDA to approve first gene therapy for Duchenne muscular dystrophy
BioPharma Dive
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
gene therapy
SRP-9001
Flag link:
Sarepta to Expedite Timeline for Muscular Dystrophy Gene Therapy
Sarepta to Expedite Timeline for Muscular Dystrophy Gene Therapy
BioSpace
Sarepta Therapeutics
SRP-9001
Duchenne Muscular Dystrophy
Flag link:
Sarepta shares buoyed by pledge to seek an early swift review for Duchenne gene therapy
Sarepta shares buoyed by pledge to seek an early swift review for Duchenne gene therapy
Fierce Biotech
Sarepta Therapeutics
SRP-9001
Duchenne Muscular Dystrophy
Roche
accelerated approvals
Flag link:
Myocarditis case mars Sarepta DMD gene therapy readout
Myocarditis case mars Sarepta DMD gene therapy readout
Pharmaforum
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
SRP-9001
myocarditis
Flag link:
Sarepta says early filing for DMD gene therapy may be back on
Sarepta says early filing for DMD gene therapy may be back on
Pharmaforum
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-9001
Flag link:
Sarepta's second-gen Duchenne drug shows signs of topping its first
Sarepta's second-gen Duchenne drug shows signs of topping its first
BioPharma Dive
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-9001
gene therapy
Flag link:
Is Sarepta Therapeutics Worthy of Redemption?
Is Sarepta Therapeutics Worthy of Redemption?
Motley Fool
Sarepta Therapeutics
SRP-9001
Duchenne Muscular Dystrophy
Flag link:
Sarepta's DMD gene therapy fails phase 2 motor function test, sinking stock
Sarepta's DMD gene therapy fails phase 2 motor function test, sinking stock
Fierce Biotech
Sarepta Therapeutics
Duchenne Muscular Dystrophy
clinical trials
SRP-9001
Flag link:
New data bolsters Sarepta gene therapies for two deadly muscle diseases
New data bolsters Sarepta gene therapies for two deadly muscle diseases
Biopharma Dive
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
Limb Girdle Muscular Dystrophy
SRP-9001
SRP-9003
Flag link:
Sarepta shares fall on potential regulatory delay for experimental Duchenne drug
Sarepta shares fall on potential regulatory delay for experimental Duchenne drug
Marketwatch
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-9001
Flag link:
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
Xconomy
Roche
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
SRP-9001
Flag link:

Pages